HomeCompareBFRA vs O

BFRA vs O: Dividend Comparison 2026

BFRA yields 4.72% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $7.0K in total portfolio value· pulled ahead in Year 7
10 years
BFRA
BFRA
● Live price
4.72%
Share price
$2.67
Annual div
$0.13
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.3K
Annual income
$638.40
Full BFRA calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — BFRA vs O

📍 O pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBFRAO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BFRA + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BFRA pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BFRA
Annual income on $10K today (after 15% tax)
$401.12/yr
After 10yr DRIP, annual income (after tax)
$542.64/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, O beats the other by $3,790.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BFRA + O for your $10,000?

BFRA: 50%O: 50%
100% O50/50100% BFRA
Portfolio after 10yr
$30.7K
Annual income
$2,868.30/yr
Blended yield
9.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

BFRA
Analyst Ratings
1
Buy
Consensus: Buy
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BFRA buys
0
O buys
0
No recent congressional trades found for BFRA or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBFRAO
Forward yield4.72%5.28%
Annual dividend / share$0.13$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$27.3K$34.2K
Annual income after 10y$638.40$5,098.20
Total dividends collected$5.6K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: BFRA vs O ($10,000, DRIP)

YearBFRA PortfolioBFRA Income/yrO PortfolioO Income/yrGap
1$11,172$471.91$10,818$607.86+$354.00BFRA
2$12,447$492.72$11,786$741.30+$661.00BFRA
3$13,831$513.03$12,944$910.50+$887.00BFRA
4$15,332$532.80$14,343$1,127.28+$989.00BFRA
5$16,957$551.98$16,053$1,408.17+$904.00BFRA
6$18,715$570.55$18,167$1,776.65+$548.00BFRA
7← crossover$20,613$588.49$20,815$2,266.60$202.00O
8$22,662$605.78$24,179$2,927.66$1.5KO
9$24,871$622.42$28,521$3,833.95$3.6KO
10$27,250$638.40$34,218$5,098.20$7.0KO

BFRA vs O: Complete Analysis 2026

BFRAStock

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Full BFRA Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this BFRA vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BFRA vs SCHDBFRA vs JEPIBFRA vs KOBFRA vs MAINBFRA vs STAGBFRA vs ADCBFRA vs NNNBFRA vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.